StreetInsider.com News Articles

Form 4 GLOBUS MEDICAL INC For: Feb 25 Filed by: Huller Kelly

Fri, 27 Feb 2026 17:54:00 -0500

si-local-file:///var/storage/secattach/20260227/26083946.html

Form 4 GLOBUS MEDICAL INC For: Feb 25 Filed by: Huller Kelly

Fri, 27 Feb 2026 17:54:00 -0500

si-local-file:///var/storage/secattach/20260227/26083946.html

Globus Medical (GMED) PT Raised to $104 at Wells Fargo

Thu, 26 Feb 2026 08:42:18 -0500

Wells Fargo analyst Vik Chopra raised the price target on Globus Medical (NYSE: GMED) to $104.00 (from $98.00) while maintaining a Overweight rating.

Form 144 GLOBUS MEDICAL INC Filed by: Huller Kelly

Wed, 25 Feb 2026 15:41:00 -0500

si-local-file:///var/storage/secattach/20260225/26059394.html

Form 144 GLOBUS MEDICAL INC Filed by: Huller Kelly

Wed, 25 Feb 2026 15:41:00 -0500

si-local-file:///var/storage/secattach/20260225/26059394.html

Globus Medical (GMED) PT Raised to $112 at TD Cowen

Wed, 25 Feb 2026 08:22:59 -0500

TD Cowen analyst Matthew Blackman raised the price target on Globus Medical (NYSE: GMED) to $112.00 (from $110.00) while maintaining a Buy rating.

The analyst comments "4Q revenue was modestly ahead of preliminary results and the '26 EPS outlook was revised higher on the continued US Spine momentum, while reaffirming revenues. GMED continues to demonstrate above-peer top-line growth, which we believe can reach/sustain DDs over time, and an earnings power story that is second-to-none in MedTech, in our view. Estimates move up, PT to $112 (from $110)."

Globus Medical (GMED) PT Raised to $112 at TD Cowen

Wed, 25 Feb 2026 08:22:59 -0500

TD Cowen analyst Matthew Blackman raised the price target on Globus Medical (NYSE: GMED) to $112.00 (from $110.00) while maintaining a Buy rating.

Globus Medical (GMED) PT Raised to $114 at Needham

Wed, 25 Feb 2026 07:10:46 -0500

Needham analyst Mike Matson raised the price target on Globus Medical (NYSE: GMED) to $114.00 (from $112.00) while maintaining a Buy rating.

The analyst comments "GMED's 4Q25 revenue was in line with its preannouncement while EPS beat consensus and management raised its 2026 EPS guidance. US Spine growth remained stable at 10% and well above the market growth while International Spine had a record quarter with expectations of growth accelerating through 2026. The robot pipeline remains strong, but the mix of placements could continue to pressure Enabling Tech's growth this year. We expect there to be further potential upside to earnings

Globus Medical (GMED) PT Raised to $114 at Needham

Wed, 25 Feb 2026 07:10:46 -0500

Needham analyst Mike Matson raised the price target on Globus Medical (NYSE: GMED) to $114.00 (from $112.00) while maintaining a Buy rating.

Globus Medical (GMED) PT Raised to $120 at Jefferies

Wed, 25 Feb 2026 05:40:53 -0500

Jefferies analyst Matthew Taylor raised the price target on Globus Medical (NYSE: GMED) to $120.00 (from $115.00) while maintaining a Buy rating.

The analyst comments "GMED reported 4Q25 sales of $826.4MM +25% xfx above the pre ~$823MM, incl core revs of $727MM +9.4% as GMED called out the best qtrly performance ever in core and ET. NVRO's integration is progressing, with sales holding up despite aggressive cost cuts. While the FY26 sales guide was inch from Jan, GMED upped EPS $0.10. We are increasing our #s and PT and see more beat and raise qtrs ahead with hiring, product momentum, and

Globus Medical (GMED) PT Raised to $120 at Jefferies

Wed, 25 Feb 2026 05:40:53 -0500

Jefferies analyst Matthew Taylor raised the price target on Globus Medical (NYSE: GMED) to $120.00 (from $115.00) while maintaining a Buy rating.

Globus Medical (GMED) PT Raised to $115 at Truist Securities

Wed, 25 Feb 2026 05:32:35 -0500

Truist Securities analyst Richard Newitter raised the price target on Globus Medical (NYSE: GMED) to $115.00 (from $105.00) while maintaining a Buy rating.

The analyst comments "Our PT goes to $115 (vs. $105 prior) based on ~13.5x & ~23x our 2027E EBITDA & EPS, respectively (and up from 13x, 22.5x prior). A ~13.5x & 23x EV/EBITDA & P/E multiple would be in-line with GMED's peer group 1-yr forward ('26E) EV/EBITDA (~13.3x) & P/E (~23.5x) respective averages. It would also be about in-line with the company's forward valuation as well as just about a 0.5x turn above GMED's avg. 4-yr NTM valuation

Globus Medical (GMED) PT Raised to $115 at Truist Securities

Wed, 25 Feb 2026 05:32:35 -0500

Truist Securities analyst Richard Newitter raised the price target on Globus Medical (NYSE: GMED) to $115.00 (from $105.00) while maintaining a Buy rating.

Globus Medical (GMED) PT Raised to $123 at Barclays

Wed, 25 Feb 2026 02:38:24 -0500

Barclays analyst Matt Miksic raised the price target on Globus Medical (NYSE: GMED) to $123.00 (from $118.00) while maintaining a Overweight rating.

Form 10-K GLOBUS MEDICAL INC For: Dec 31

Tue, 24 Feb 2026 17:09:00 -0500

si-local-file:///var/storage/secattach/20260224/26052921.html

Form 10-K GLOBUS MEDICAL INC For: Dec 31

Tue, 24 Feb 2026 17:09:00 -0500

si-local-file:///var/storage/secattach/20260224/26052921.html

Globus Medical (GMED) Tops Q4 EPS by 17c, provides guidance

Tue, 24 Feb 2026 16:25:39 -0500

Globus Medical (NYSE: GMED) reported Q4 EPS of $1.28, $0.17 better than the analyst estimate of $1.11. Revenue for the quarter came in at $826.4 million versus the consensus estimate of $792.72 million.

GUIDANCE:

Globus Medical sees FY2026 EPS of $4.40-$4.50, versus the consensus of $4.24. Globus Medical sees FY2026 revenue of $3.18-3.22 billion, versus the consensus of $3.163 billion.

For earnings history and earnings-related data on Globus Medical (GMED) click here.

Globus Medical (GMED) Tops Q4 EPS by 17c, provides guidance

Tue, 24 Feb 2026 16:25:39 -0500

GUIDANCE:

Globus Medical sees FY2026 EPS of $4.40-$4.50, versus the consensus of $4.24. Globus Medical sees FY2026 revenue of $3.18-3.22 billion, versus the consensus of $3.163 billion.

For earnings history and earnings-related data on Globus Medical (GMED) click here.

Form 8-K GLOBUS MEDICAL INC For: Feb 24

Tue, 24 Feb 2026 16:24:00 -0500

si-local-file:///var/storage/secattach/20260224/26051953.html

Form 8-K GLOBUS MEDICAL INC For: Feb 24

Tue, 24 Feb 2026 16:24:00 -0500

si-local-file:///var/storage/secattach/20260224/26051953.html

Globus Medical Reports Fourth Quarter and Full Year 2025 Results

Tue, 24 Feb 2026 16:15:00 -0500

AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2025.

Fourth Quarter 2025:

Worldwide net sales were $826.4 million, an increase of 25.7%, or an increase of 24.7% on a constant currency basis.
Base business, excluding Nevro, net sales were $726.7 million, an increase of 10.6%, or an increase of 9.4% on a constant currency basis.
GAAP net income for the quarter was $140.6 million.
GAAP diluted earnings per share (“EPS”)

Globus Medical Reports Fourth Quarter and Full Year 2025 Results

Tue, 24 Feb 2026 16:15:00 -0500

Fourth Quarter 2025:

Worldwide net sales were $826.4 million, an increase of 25.7%, or an increase of 24.7% on a constant currency basis.
Base business, excluding Nevro, net sales were $726.7 million, an increase of 10.6%, or an increase of 9.4% on a constant currency basis.
GAAP net income for the quarter was $140.6 million.
GAAP diluted earnings per share (“EPS”)

Form 4 GLOBUS MEDICAL INC For: Feb 12 Filed by: Huller Kelly

Tue, 17 Feb 2026 17:23:00 -0500

si-local-file:///var/storage/secattach/20260217/26015260.html

Form 4 GLOBUS MEDICAL INC For: Feb 12 Filed by: Huller Kelly

Tue, 17 Feb 2026 17:23:00 -0500

si-local-file:///var/storage/secattach/20260217/26015260.html

Globus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

Thu, 12 Feb 2026 16:30:00 -0500

AUDUBON, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2025 after the market close on Tuesday, February 24, 2026. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.

Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus